Sign In

Clinton Musil

CBO at Personalis, Inc.

Clinton Musil is the Chief Executive Officer of Skyhawk Therapeutics, having been promoted from his previous role as Chief Financial Officer in June 2024.12 He brings decades of experience in the biopharmaceutical industry, with expertise in strategic planning, financial management, and a broad range of transactions including financings, pharmaceutical partnerships, and mergers and acquisitions.1

Musil's career highlights include:

  1. Completing multiple IPOs and serving in several public biotech company executive roles.1
  2. Working at ARMO BioSciences, which was sold to Eli Lilly for $1.6 billion.14
  3. Serving as Chief Financial Officer at Catalyst Biosciences from June 2020 to September 2021.23
  4. Working as Chief Business Officer at Personalis, Inc. from 2018 to June 2020.24
  5. Holding roles in corporate development and investment banking at companies like Deutsche Bank and Wells Fargo Securities.2

Musil holds an M.B.A. from Harvard Business School and a B.S. in Molecular and Cellular Biology from the University of Arizona.12 His LinkedIn username is clinton-musil.

Highlights

Jun 15 · globenewswire.com
Catalyst Biosciences Appoints Clinton Musil as Chief Financial Officer
Personalis Appoints Biotech Industry Executive Clinton Musil as ...

Related Questions

What are Clint Musil's main responsibilities as CEO of Skyhawk Therapeutics?
How did Clint Musil's career progress before becoming CEO at Skyhawk Therapeutics?
What are the key achievements of Clint Musil in the biopharmaceutical industry?
How does Clint Musil's background in finance and corporate development influence his leadership at Skyhawk Therapeutics?
What are the future plans and goals for Skyhawk Therapeutics under Clint Musil's leadership?
Clinton Musil
Clinton Musil, photo 1
Clinton Musil, photo 2
Add to my network

Location

San Francisco, California